THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA

THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA

Show other versions (1)

abstract Background: Beta thalassemia is an inherited hemoglobin disorder resulting in chronic hemolytic anemia requiring life-long blood transfusion that cause iron overload. Silymarin plays a role as oral iron chelator and hepatoprotective agents in thalassemic patients.The aim of this work was to...

Full description

Bibliographic Details
Main Author:	adel abd elhaleim hagag
Format:	Article
Language:	English
Published:	PAGEPress Publications 2013-11-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Subjects:	thalassemia
Online Access:	http://www.mjhid.org/index.php/mjhid/article/view/458

Similar Items

Therapeutic Value of Silymarin as Iron Chelator in Children with Beta Thalassemia with Iron Overload
by: adel abd elhaleim hagag
Published: (2014-08-01)

Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia
by: adel abd elhaleim hagag
Published: (2014-08-01)

Comparative study of efficacy of different iron chelating agents in treatment of iron overload in children with Beta Thalassemia Major
by: adel abd elhaleim hagag
Published: (2014-08-01)

Study of T lymphocyte Subsets in children with Beta Thalassemia Major: Correlation with iron overload Adel A. Hagag, Mokhtar A. Hussein, Enaam S. Abed Elbar* From Pediatrics and Clinical Pathology*departments, Faculty of Medicine, Tanta University, Egy
by: adel abd elhaleim hagag
Published: (2014-08-01)

Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major
by: Hossein Karami, et al.
Published: (2017-01-01)

SPECTRUM OF BETA GLOBIN GENE MUTATIONS IN EGYPTIAN CHILDREN WITH β- THALASSEMIA
by: MR El-Shanshory, et al.
Published: (2014-08-01)

Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia
by: Murtadha Al-Khabori, et al.
Published: (2013-03-01)

Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia
by: Hayder M Al-Kuraishy, et al.
Published: (2017-01-01)

A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan
by: Wan-Ling Ho, et al.
Published: (2013-04-01)

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
by: Mohamed Abdel Malik Hassan, et al.
Published: (2016-05-01)

Iron overload in non-transfusion-dependent thalassemia
by: Khaled M. Musallam
Published: (2013-03-01)

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
by: Shahla Ansari, et al.
Published: (2017-06-01)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
by: Kontoghiorghe CN, et al.
Published: (2016-01-01)

DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
by: Ali Taher
Published: (2018-11-01)

Correlation of Renal Function with Liver Iron Overload in Beta-Thalassemia Major Patients
by: H Mahmoodi Nesheli,, et al.
Published: (2013-01-01)

THE ANTIOXIDANT EFFECTS OF CAPPARIS OVATA AND DEFERASIROX IN PATIENTS WITH THALASSEMIA MAJOR
by: Handan Duman, et al.
Published: (2014-08-01)

ANALYSIS OF DEFERASIROX AND DEFERIPRON USE IN CHILDREN WITH PEDIATRIC -THALASSEMIA MAJOR
by: Evy Sari Sutrisnaningsih, et al.
Published: (2017-08-01)

Comparison of deferasirox and deferoxamine effect on liver enzyme activities and ferritin level in patients with beta-thalassemia
by: Rasul Jameel Ali, et al.
Published: (2020-12-01)

Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series
by: Valeria Maria Pinto, et al.
Published: (2020-11-01)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
by: Taher AT, et al.
Published: (2016-12-01)

Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
by: Ricchi P, et al.
Published: (2015-12-01)

Iron deficiency anemia: an instrument in the propagation of beta thalassemia gene
by: Muhammad Usman
Published: (2014-08-01)

Hepcidin gene polymorphisms and iron overload in β-thalassemia major patients refractory to iron chelating therapy
by: Parinaz Zarghamian, et al.
Published: (2020-04-01)

Glutathione S transferase polymorphisms influence on iron overload in β-thalassemia patients
by: Serena Sclafani, et al.
Published: (2013-11-01)

Study of the effect of HFE gene mutations on iron overload in Egyptian thalassemia patients
by: Manal Michel Wilson, et al.
Published: (2015-04-01)

Study of the effect of iron overload on the function of endocrine glands in male thalassemia patients
by: Abdulzahra Mohammed, et al.
Published: (2011-01-01)

Liver iron overload and hepatic function in children with thalassemia major
by: Pustika Amalia Wahidiyat, et al.
Published: (2018-09-01)

Oxidative Stress (Malondialdehyde) in Adults Beta-Thalassemia Major and Intermedia: Comparison Between Before and After Blood Transfusion and Its Correlation with Iron Overload
by: Atmakusuma TD, et al.
Published: (2021-10-01)

Sublethal iron overload can alter the morphology and function of dendritic cells which may predispose to gram-negative infection in beta-thalassemia
by: Dee, Cathleen Michelle Ang, et al.
Published: (2015)

Iron overload and chelation therapy in hemoglobinopathies
by: Rayan Bou-Fakhredin, et al.
Published: (2018-04-01)

Prevalence of Co-Inheritance of Alpha-Thalassemia with Beta-Thalassemia and Beta-Hemoglobinopathy in Ahvaz City
by: Najmaddin Saki, et al.
Published: (2013-09-01)

Effect of Combined versus Monotherapy with Deferoxamine and Deferiprone in Iron Overloaded Thalassemia Patients: a Randomized Clinical Trial
by: Sasan Hejazi, et al.
Published: (2016-06-01)

Urinary Metabolic Profile of Patients with Transfusion-Dependent β-Thalassemia Major Undergoing Deferasirox Therapy
by: Giovanna Capolongo, et al.
Published: (2020-05-01)

Pengaruh Deferasirox Terhadap Kadar T4 dan TSH Pada B-Thalassemia Mayor dengan Kadar Ferritin Tinggi
by: Dewi Ratih P, et al.
Published: (2016-11-01)

Lens opacity as a serious side effect following chelation therapy in beta thalassemia: A comparison between deferoxamine and deferasirox; randomized double-blinded clinical trial
by: Mohammad Reza Golpayegani, et al.
Published: (2019-01-01)

Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report
by: Pustika Amalia Wahidiyat, et al.
Published: (2018-06-01)

Pathogen-Associated Molecules from Gut Translocation Enhance Severity of Cecal Ligation and Puncture Sepsis in Iron-Overload β-Thalassemia Mice
by: Sae-khow K, et al.
Published: (2020-10-01)

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
by: Rayan Bou-Fakhredin, et al.
Published: (2017-12-01)

Hypoparathyroidism in Adult Patients with Beta-Thalassemia Major
by: Gihan Ali A M Sleem, et al.
Published: (2007-12-01)

Pulmonary dysfunction in children with beta thalassemia major in relation with iron overload - a cross sectional hospital based study
by: A Boddu
Published: (2015-04-01)